KPRX Kiora Pharmaceuticals (KPRX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001372514
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
13
13F, latest reported quarter
Kiora Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for KIORA PHARMACEUTICALS INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 1,250 shares held after it.
- 4 other insiders bought within 30 days.
- 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Stengone Carmine N. bought about $4.6K of KPRX on Sep 11, 2024; 4 other insiders bought within 30 days and 13 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 3,000 shares held after it.
- 4 other insiders bought within 30 days.
- 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Shapiro Aron bought about $10.8K of KPRX on Sep 10, 2024; 4 other insiders bought within 30 days and 13 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 1,250 shares held after it.
- 4 other insiders bought within 30 days.
- 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Walters-Hoffert Lisa bought about $4.8K of KPRX on Aug 19, 2024; 4 other insiders bought within 30 days and 13 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 99.7% of the 5,014 shares held after it.
- 4 other insiders bought within 30 days.
- 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director TYLE PRAVEEN bought about $19.8K of KPRX on Aug 19, 2024; 4 other insiders bought within 30 days and 13 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jun 14, 2024.
- The trade is 14.7% of the 13,599 shares held after it.
- 4 other insiders bought within 30 days.
- 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO Tosca Melissa bought about $6.4K of KPRX on Aug 14, 2024; 4 other insiders bought within 30 days and 13 funds added in the latest 13F quarter.10 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
13 funds bought in last quarter
below 77% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.1% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 89% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch KPRX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-13.0%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns KPRX: institutional holders (13F)
13F holdings, latest reported quarter
438,471 sh
$1.2M
167,941 sh
$441.7K
116,011 sh
$305.1K
88,792 sh
$233.5K
74,202 sh
$195.2K
Congress trades in KPRX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
KPRX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
KPRX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Omni Small-Cap Value Fund
$5.3K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$96.4K position · as of 2026-05-31
0.0%
U.S. VECTOR EQUITY PORTFOLIO
$10.3K position · as of 2026-07-31
0.0%
U.S. Social Core Equity 2 Portfolio
$3.2K position · as of 2026-07-31
0.0%
Dimensional US Core Equity 1 ETF
$4.1K position · as of 2026-07-31
0.0%
U.S. Sustainability Core 1 Portfolio
$5.0K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
4
Phase 2
2 active
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 13 funds added last quarter. Each figure is a federal filing, dated the day it went public.
KPRX financials
Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-01-01 to 2025-12-31
Revenue, TTM KPRX
| FY Dec 2025 | $0 |
| FY Dec 2024 | $16.0M |
| FY Dec 2023 | $0 |
| FY Dec 2022 | $12.1K |
| FY Dec 2021 | $12.1K |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | $0 |
| Sep 2025 | $0 |
| Jun 2025 | $0 |
| Mar 2025 | $0 |
| Dec 2024 | $0 |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM KPRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | +0.0% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$8.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM KPRX
| FY Dec 2025 | -$10.1M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -$10.5M |
| FY Dec 2021 | -$10.7M |
| Jun 2026 | -$1.9M |
| Mar 2026 | -$3.2M |
| Dec 2025 | -$2.3M |
| Sep 2025 | -$1.3M |
| Jun 2025 | -$3.8M |
| Mar 2025 | -$2.7M |
| Dec 2024 | -$2.2M |
| Sep 2024 | $920.1K |
At each fiscal year end
Single quarter
Debt to equity
0.02x
long-term debt only, 2021-03-31 (63 months older than the period end); equity 2026-06-30
Debt to equity KPRX
| FY Dec 2025 | 0.02x |
| FY Dec 2024 | 0.01x |
| FY Dec 2023 | 0.05x |
| FY Dec 2022 | 0.02x |
| FY Dec 2021 | 0.02x |
| Jun 2026 | 0.02x |
| Mar 2026 | 0.02x |
| Dec 2025 | 0.02x |
| Sep 2025 | 0.01x |
| Jun 2025 | 0.01x |
| Mar 2025 | 0.01x |
| Dec 2024 | 0.01x |
| Sep 2024 | 0.01x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-30.58x
TTM operating cash flow over long-term debt only, 2021-03-31 (63 months older than the period end)
Cash flow to debt KPRX
| FY Dec 2025 | -35.81x |
| FY Dec 2024 | 30.77x |
| FY Dec 2023 | -34.35x |
| FY Dec 2022 | -37.49x |
| FY Dec 2021 | -38.37x |
| Jun 2026 | -30.58x |
| Mar 2026 | -37.45x |
| Dec 2025 | -35.81x |
| Sep 2025 | -36.07x |
| Jun 2025 | -28.18x |
| Mar 2025 | -27.93x |
| Dec 2024 | 30.77x |
| Sep 2024 | 29.58x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-0.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity KPRX
| FY Dec 2025 | -0.1% |
| FY Dec 2024 | +0.0% |
| FY Dec 2023 | -0.1% |
| FY Dec 2022 | -104.5% |
| FY Dec 2021 | -113.3% |
| Jun 2026 | -0.8% |
| Mar 2026 | -1.3% |
| Dec 2025 | -0.1% |
| Sep 2025 | -46.3% |
| Jun 2025 | -56.4% |
| Mar 2025 | -53.4% |
| Dec 2024 | +0.0% |
| Sep 2024 | +94.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-0.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets KPRX
| FY Dec 2025 | -0.0% |
| FY Dec 2024 | +0.0% |
| FY Dec 2023 | -0.1% |
| FY Dec 2022 | -70.0% |
| FY Dec 2021 | -77.7% |
| Jun 2026 | -0.6% |
| Mar 2026 | -0.9% |
| Dec 2025 | -0.0% |
| Sep 2025 | -35.5% |
| Jun 2025 | -42.8% |
| Mar 2025 | -40.9% |
| Dec 2024 | +0.0% |
| Sep 2024 | +66.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital KPRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | +21.9% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | +21.9% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-51.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed KPRX
| FY Dec 2025 | -50.2% |
| FY Dec 2024 | +21.2% |
| FY Dec 2023 | -91.6% |
| FY Dec 2022 | -72.6% |
| FY Dec 2021 | -89.4% |
| Jun 2026 | -51.1% |
| Mar 2026 | -55.2% |
| Dec 2025 | -50.2% |
| Sep 2025 | -26.0% |
| Jun 2025 | -32.1% |
| Mar 2025 | -31.7% |
| Dec 2024 | +21.2% |
| Sep 2024 | +20.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing KPRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | 3.06x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | 3.06x |
| Sep 2024 | 3.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$3.0M
market value at close 2026-10-26 on 2026-08-05 shares, plus long-term debt only, 2021-03-31 (63 months older than the period end), minus cash 2026-06-30
Enterprise value KPRX
| FY Dec 2025 | -$1.2M |
| FY Dec 2024 | $6.4M |
| FY Dec 2023 | $33.9M |
| FY Dec 2022 | $29.6M |
| FY Dec 2021 | $6.9B |
| Jun 2026 | $4.9M |
| Mar 2026 | -$3.1M |
| Dec 2025 | -$1.2M |
| Sep 2025 | $4.3M |
| Jun 2025 | $8.0M |
| Mar 2025 | $5.5M |
| Dec 2024 | $6.4M |
| Sep 2024 | $5.5M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-88.1%
TTM free cash flow over market value at close 2026-10-26
FCF yield KPRX
| FY Dec 2025 | -139.0% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -29.8% |
| FY Dec 2021 | -0.2% |
| Jun 2026 | -73.9% |
| Mar 2026 | -138.2% |
| Dec 2025 | -139.0% |
| Sep 2025 | -105.0% |
| Jun 2025 | -89.3% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing KPRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $0 | $16.0M | $0 | n/a |
| Operating income | -$12.8M | $4.5M | -$12.6M | -$12.3M |
| Net income | -$10.8K | $3.6K | -$12.5K | -$13.6M |
| EPS (diluted) | n/a | 0.87 | n/a | -18.55 |
| Operating cash flow | -$10.0M | $8.6M | -$9.6M | -$10.4M |
| Cash | $8.7M | $3.8M | $2.5M | $6.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
KPRX Stock Sonar score 5/7 axes
Find similar shapesCompareKPRX ranks highest on risk and compliance (91st percentile) and profitability (70th), and lowest on growth (1st), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
